Search

Your search keyword '"Balli, David"' showing total 127 results
Start Over Author "Balli, David"
127 results on '"Balli, David"'

1. Association between pathologic response and survival after neoadjuvant therapy in lung cancer

Author

Deutsch, Julie Stein, Cimino-Mathews, Ashley, Thompson, Elizabeth, Provencio, Mariano, Forde, Patrick M., Spicer, Jonathan, Girard, Nicolas, Wang, Daphne, Anders, Robert A., Gabrielson, Edward, Illei, Peter, Jedrych, Jaroslaw, Danilova, Ludmila, Sunshine, Joel, Kerr, Keith M., Tran, Mia, Bushong, Judith, Cai, Junliang, Devas, Vipul, Neely, Jaclyn, Balli, David, Cottrell, Tricia R., Baras, Alex S., and Taube, Janis M.

Published
2024
Full Text
View/download PDF

2. Calcium signaling induces a partial EMT.

Author

Norgard, Robert, Pitarresi, Jason, Maddipati, Ravikanth, Aiello-Couzo, Nicole, Balli, David, Li, Jinyang, Yamazoe, Taiji, Wengyn, Maximilian, Millstein, Ian, Folkert, Ian, Rosario-Berrios, Derick, Kim, Il-Kyu, Bassett, Jared, Payne, Riley, Berry, Corbett, Feng, Xiaodong, Sun, Kathryn, Cioffi, Michele, Chakraborty, Priyanka, Jolly, Mohit, Gutkind, J, Lyden, David, Freedman, Bruce, Foskett, J, Rustgi, Anil, and Stanger, Ben

Subjects
E-cadherin, calcium, cellular plasticity, partial EMT, Cadherins, Calcium Signaling, Cell Line, Tumor, Cell Movement, Cell Plasticity, Epithelial-Mesenchymal Transition
Abstract

Epithelial plasticity, or epithelial-to-mesenchymal transition (EMT), is a well-recognized form of cellular plasticity, which endows tumor cells with invasive properties and alters their sensitivity to various agents, thus representing a major challenge to cancer therapy. It is increasingly accepted that carcinoma cells exist along a continuum of hybrid epithelial-mesenchymal (E-M) states and that cells exhibiting such partial EMT (P-EMT) states have greater metastatic competence than those characterized by either extreme (E or M). We described recently a P-EMT program operating in vivo by which carcinoma cells lose their epithelial state through post-translational programs. Here, we investigate the underlying mechanisms and report that prolonged calcium signaling induces a P-EMT characterized by the internalization of membrane-associated E-cadherin (ECAD) and other epithelial proteins as well as an increase in cellular migration and invasion. Signaling through Gαq-associated G-protein-coupled receptors (GPCRs) recapitulates these effects, which operate through the downstream activation of calmodulin-Camk2b signaling. These results implicate calcium signaling as a trigger for the acquisition of hybrid/partial epithelial-mesenchymal states in carcinoma cells.

Published
2021

4. Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction

Author

Wells, Daniel K, van Buuren, Marit M, Dang, Kristen K, Hubbard-Lucey, Vanessa M, Sheehan, Kathleen CF, Campbell, Katie M, Lamb, Andrew, Ward, Jeffrey P, Sidney, John, Blazquez, Ana B, Rech, Andrew J, Zaretsky, Jesse M, Comin-Anduix, Begonya, Ng, Alphonsus HC, Chour, William, Yu, Thomas V, Rizvi, Hira, Chen, Jia M, Manning, Patrice, Steiner, Gabriela M, Doan, Xengie C, Alliance, The Tumor Neoantigen Selection, Khan, Aly A, Lugade, Amit, Lazic, Ana M Mijalkovic, Frentzen, Angela A Elizabeth, Tadmor, Arbel D, Sasson, Ariella S, Rao, Arjun A, Pei, Baikang, Schrörs, Barbara, Berent-Maoz, Beata, Carreno, Beatriz M, Song, Bin, Peters, Bjoern, Li, Bo, Higgs, Brandon W, Stevenson, Brian J, Iseli, Christian, Miller, Christopher A, Morehouse, Christopher A, Melief, Cornelis JM, Puig-Saus, Cristina, van Beek, Daphne, Balli, David, Gfeller, David, Haussler, David, Jäger, Dirk, Cortes, Eduardo, Esaulova, Ekaterina, Sherafat, Elham, Arcila, Francisco, Bartha, Gabor, Liu, Geng, Coukos, George, Richard, Guilhem, Chang, Han, Si, Han, Zörnig, Inka, Xenarios, Ioannis, Mandoiu, Ion, Kooi, Irsan, Conway, James P, Kessler, Jan H, Greenbaum, Jason A, Perera, Jason F, Harris, Jason, Hundal, Jasreet, Shelton, Jennifer M, Wang, Jianmin, Wang, Jiaqian, Greshock, Joel, Blake, Jonathon, Szustakowski, Joseph, Kodysh, Julia, Forman, Juliet, Wei, Lei, Lee, Leo J, Fanchi, Lorenzo F, Slagter, Maarten, Lang, Maren, Mueller, Markus, Lower, Martin, Vormehr, Mathias, Artyomov, Maxim N, Kuziora, Michael, Princiotta, Michael, Bassani-Sternberg, Michal, Macabali, Mignonette, Kojicic, Milica R, Yang, Naibo, Raicevic, Nevena M Ilic, Guex, Nicolas, Robine, Nicolas, Halama, Niels, Skundric, Nikola M, Milicevic, Ognjen S, Gellert, Pascal, Jongeneel, Patrick, and Charoentong, Pornpimol

Subjects
Biological Sciences, Bioinformatics and Computational Biology, Biomedical and Clinical Sciences, Immunology, Cancer, Vaccine Related, Genetics, Immunization, Good Health and Well Being, Alleles, Antigen Presentation, Antigens, Neoplasm, Cohort Studies, Epitopes, Humans, Neoplasms, Peptides, Programmed Cell Death 1 Receptor, Reproducibility of Results, Tumor Neoantigen Selection Alliance, TESLA, epitope, immunogenicity, immunogenomics, immunotherapy, neoantigen, Medical and Health Sciences, Developmental Biology, Biological sciences, Biomedical and clinical sciences
Abstract

Many approaches to identify therapeutically relevant neoantigens couple tumor sequencing with bioinformatic algorithms and inferred rules of tumor epitope immunogenicity. However, there are no reference data to compare these approaches, and the parameters governing tumor epitope immunogenicity remain unclear. Here, we assembled a global consortium wherein each participant predicted immunogenic epitopes from shared tumor sequencing data. 608 epitopes were subsequently assessed for T cell binding in patient-matched samples. By integrating peptide features associated with presentation and recognition, we developed a model of tumor epitope immunogenicity that filtered out 98% of non-immunogenic peptides with a precision above 0.70. Pipelines prioritizing model features had superior performance, and pipeline alterations leveraging them improved prediction performance. These findings were validated in an independent cohort of 310 epitopes prioritized from tumor sequencing data and assessed for T cell binding. This data resource enables identification of parameters underlying effective anti-tumor immunity and is available to the research community.

Published
2020

5. First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations

Author

Paz-Ares, Luis G., Ciuleanu, Tudor-Eliade, Cobo, Manuel, Bennouna, Jaafar, Schenker, Michael, Cheng, Ying, Juan-Vidal, Oscar, Mizutani, Hideaki, Lingua, Alejo, Reyes-Cosmelli, Felipe, Reinmuth, Niels, Menezes, Juliana, Jassem, Jacek, Protsenko, Svetlana, Richardet, Eduardo, Felip, Enriqueta, Feeney, Kynan, Zurawski, Bogdan, Alexandru, Aurelia, de la Mora Jimenez, Emmanuel, Dakhil, Shaker, Lu, Shun, Reck, Martin, John, Thomas, Hu, Nan, Zhang, Xiaoqing, Sylvester, Judi, Eccles, Laura J., Grootendorst, Diederik J., Balli, David, Neely, Jaclyn, and Carbone, David P.

Published
2023
Full Text
View/download PDF

8. 972 Platinum-based chemotherapy reverses human MDSC phenotype and suppressive activity on CD8+ T cells

Author

Ding, Yueyun, primary, Schrand, Ailem, additional, DeBettencourt, Joe, additional, Lako, Ana, additional, Rai, Sharmila Chamling, additional, Tauras, Christine, additional, Bleicher, Zoe, additional, Consedine, Timothy, additional, George, Sangeeth, additional, Balli, David, additional, Simpson, Tyler, additional, Geese, William J, additional, Bhatt, Rupal, additional, Chen, Benjamin, additional, and Ramirez-Alejo, Noe, additional

Published
2023
Full Text
View/download PDF

9. 222-N Analysis of pathologic features and efficacy outcomes with neoadjuvant nivolumab plus platinum-doublet chemotherapy for resectable non-small cell lung cancer in CheckMate 816

Author

Deutsch, Julie Stein, primary, Cimino-Mathews, Ashley, additional, Thompson, Elizabeth, additional, Provencio, Mariano, additional, Forde, Patrick M, additional, Spicer, Jonathan, additional, Girard, Nicolas, additional, Wang, Daphne, additional, Anders, Robert A, additional, Gabrielson, Edward, additional, Illei, Peter, additional, Jedrych, Jaroslaw, additional, Danilova, Ludmila, additional, Sunshine, Joel, additional, Kerr, Keith M, additional, Tran, Mia, additional, Bushong, Judy, additional, Cai, Junliang, additional, Devas, Vipul, additional, Neely, Jaclyn, additional, Balli, David, additional, Cottrell, Tricia R, additional, Baras, Alex S, additional, and Taube, Janis, additional

Published
2023
Full Text
View/download PDF

10. Deep computational image analysis of immune cell niches reveals treatment-specific outcome associations in lung cancer

Author

Barrera, Cristian, primary, Corredor, Germán, additional, Viswanathan, Vidya Sankar, additional, Ding, Ruiwen, additional, Toro, Paula, additional, Fu, Pingfu, additional, Buzzy, Christina, additional, Lu, Cheng, additional, Velu, Priya, additional, Zens, Philipp, additional, Berezowska, Sabina, additional, Belete, Merzu, additional, Balli, David, additional, Chang, Han, additional, Baxi, Vipul, additional, Syrigos, Konstantinos, additional, Rimm, David L., additional, Velcheti, Vamsidhar, additional, Schalper, Kurt, additional, Romero, Eduardo, additional, and Madabhushi, Anant, additional

Published
2023
Full Text
View/download PDF

11. Supplementary Data from MYC Levels Regulate Metastatic Heterogeneity in Pancreatic Adenocarcinoma

Author

Maddipati, Ravikanth, primary, Norgard, Robert J., primary, Baslan, Timour, primary, Rathi, Komal S., primary, Zhang, Amy, primary, Saeid, Asal, primary, Higashihara, Taku, primary, Wu, Feng, primary, Kumar, Angad, primary, Annamalai, Valli, primary, Bhattacharya, Saurav, primary, Raman, Pichai, primary, Adkisson, Christian A., primary, Pitarresi, Jason R., primary, Wengyn, Maximilian D., primary, Yamazoe, Taiji, primary, Li, Jinyang, primary, Balli, David, primary, LaRiviere, Michael J., primary, Ngo, Tuong-Vi C., primary, Folkert, Ian W., primary, Millstein, Ian D., primary, Bermeo, Jonathan, primary, Carpenter, Erica L., primary, McAuliffe, John C., primary, Oktay, Maja H., primary, Brekken, Rolf A., primary, Lowe, Scott W., primary, Iacobuzio-Donahue, Christine A., primary, Notta, Faiyaz, primary, and Stanger, Ben Z., primary

Published
2023
Full Text
View/download PDF

12. Supplementary Figure from MYC Levels Regulate Metastatic Heterogeneity in Pancreatic Adenocarcinoma

Author

Maddipati, Ravikanth, primary, Norgard, Robert J., primary, Baslan, Timour, primary, Rathi, Komal S., primary, Zhang, Amy, primary, Saeid, Asal, primary, Higashihara, Taku, primary, Wu, Feng, primary, Kumar, Angad, primary, Annamalai, Valli, primary, Bhattacharya, Saurav, primary, Raman, Pichai, primary, Adkisson, Christian A., primary, Pitarresi, Jason R., primary, Wengyn, Maximilian D., primary, Yamazoe, Taiji, primary, Li, Jinyang, primary, Balli, David, primary, LaRiviere, Michael J., primary, Ngo, Tuong-Vi C., primary, Folkert, Ian W., primary, Millstein, Ian D., primary, Bermeo, Jonathan, primary, Carpenter, Erica L., primary, McAuliffe, John C., primary, Oktay, Maja H., primary, Brekken, Rolf A., primary, Lowe, Scott W., primary, Iacobuzio-Donahue, Christine A., primary, Notta, Faiyaz, primary, and Stanger, Ben Z., primary

Published
2023
Full Text
View/download PDF

13. Data from MYC Levels Regulate Metastatic Heterogeneity in Pancreatic Adenocarcinoma

Author

Maddipati, Ravikanth, primary, Norgard, Robert J., primary, Baslan, Timour, primary, Rathi, Komal S., primary, Zhang, Amy, primary, Saeid, Asal, primary, Higashihara, Taku, primary, Wu, Feng, primary, Kumar, Angad, primary, Annamalai, Valli, primary, Bhattacharya, Saurav, primary, Raman, Pichai, primary, Adkisson, Christian A., primary, Pitarresi, Jason R., primary, Wengyn, Maximilian D., primary, Yamazoe, Taiji, primary, Li, Jinyang, primary, Balli, David, primary, LaRiviere, Michael J., primary, Ngo, Tuong-Vi C., primary, Folkert, Ian W., primary, Millstein, Ian D., primary, Bermeo, Jonathan, primary, Carpenter, Erica L., primary, McAuliffe, John C., primary, Oktay, Maja H., primary, Brekken, Rolf A., primary, Lowe, Scott W., primary, Iacobuzio-Donahue, Christine A., primary, Notta, Faiyaz, primary, and Stanger, Ben Z., primary

Published
2023
Full Text
View/download PDF

15. Supplemental Table 2 from Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA

Author

Thompson, Jeffrey C., primary, Yee, Stephanie S., primary, Troxel, Andrea B., primary, Savitch, Samantha L., primary, Fan, Ryan, primary, Balli, David, primary, Lieberman, David B., primary, Morrissette, Jennifer D., primary, Evans, Tracey L., primary, Bauml, Joshua, primary, Aggarwal, Charu, primary, Kosteva, John A., primary, Alley, Evan, primary, Ciunci, Christine, primary, Cohen, Roger B., primary, Bagley, Stephen, primary, Stonehouse-Lee, Susan, primary, Sherry, Victoria E., primary, Gilbert, Elizabeth, primary, Langer, Corey, primary, Vachani, Anil, primary, and Carpenter, Erica L., primary

Published
2023
Full Text
View/download PDF

16. Supplemental Table 3 from Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA

Author

Thompson, Jeffrey C., primary, Yee, Stephanie S., primary, Troxel, Andrea B., primary, Savitch, Samantha L., primary, Fan, Ryan, primary, Balli, David, primary, Lieberman, David B., primary, Morrissette, Jennifer D., primary, Evans, Tracey L., primary, Bauml, Joshua, primary, Aggarwal, Charu, primary, Kosteva, John A., primary, Alley, Evan, primary, Ciunci, Christine, primary, Cohen, Roger B., primary, Bagley, Stephen, primary, Stonehouse-Lee, Susan, primary, Sherry, Victoria E., primary, Gilbert, Elizabeth, primary, Langer, Corey, primary, Vachani, Anil, primary, and Carpenter, Erica L., primary

Published
2023
Full Text
View/download PDF

17. Supplemental Table 6 from Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA

Author

Thompson, Jeffrey C., primary, Yee, Stephanie S., primary, Troxel, Andrea B., primary, Savitch, Samantha L., primary, Fan, Ryan, primary, Balli, David, primary, Lieberman, David B., primary, Morrissette, Jennifer D., primary, Evans, Tracey L., primary, Bauml, Joshua, primary, Aggarwal, Charu, primary, Kosteva, John A., primary, Alley, Evan, primary, Ciunci, Christine, primary, Cohen, Roger B., primary, Bagley, Stephen, primary, Stonehouse-Lee, Susan, primary, Sherry, Victoria E., primary, Gilbert, Elizabeth, primary, Langer, Corey, primary, Vachani, Anil, primary, and Carpenter, Erica L., primary

Published
2023
Full Text
View/download PDF

18. Supplemental Table 1 from Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA

Author

Thompson, Jeffrey C., primary, Yee, Stephanie S., primary, Troxel, Andrea B., primary, Savitch, Samantha L., primary, Fan, Ryan, primary, Balli, David, primary, Lieberman, David B., primary, Morrissette, Jennifer D., primary, Evans, Tracey L., primary, Bauml, Joshua, primary, Aggarwal, Charu, primary, Kosteva, John A., primary, Alley, Evan, primary, Ciunci, Christine, primary, Cohen, Roger B., primary, Bagley, Stephen, primary, Stonehouse-Lee, Susan, primary, Sherry, Victoria E., primary, Gilbert, Elizabeth, primary, Langer, Corey, primary, Vachani, Anil, primary, and Carpenter, Erica L., primary

Published
2023
Full Text
View/download PDF

20. Supplemental Table 7 from Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA

Author

Thompson, Jeffrey C., primary, Yee, Stephanie S., primary, Troxel, Andrea B., primary, Savitch, Samantha L., primary, Fan, Ryan, primary, Balli, David, primary, Lieberman, David B., primary, Morrissette, Jennifer D., primary, Evans, Tracey L., primary, Bauml, Joshua, primary, Aggarwal, Charu, primary, Kosteva, John A., primary, Alley, Evan, primary, Ciunci, Christine, primary, Cohen, Roger B., primary, Bagley, Stephen, primary, Stonehouse-Lee, Susan, primary, Sherry, Victoria E., primary, Gilbert, Elizabeth, primary, Langer, Corey, primary, Vachani, Anil, primary, and Carpenter, Erica L., primary

Published
2023
Full Text
View/download PDF

21. Supplemental Figure 1 from Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA

Author

Thompson, Jeffrey C., primary, Yee, Stephanie S., primary, Troxel, Andrea B., primary, Savitch, Samantha L., primary, Fan, Ryan, primary, Balli, David, primary, Lieberman, David B., primary, Morrissette, Jennifer D., primary, Evans, Tracey L., primary, Bauml, Joshua, primary, Aggarwal, Charu, primary, Kosteva, John A., primary, Alley, Evan, primary, Ciunci, Christine, primary, Cohen, Roger B., primary, Bagley, Stephen, primary, Stonehouse-Lee, Susan, primary, Sherry, Victoria E., primary, Gilbert, Elizabeth, primary, Langer, Corey, primary, Vachani, Anil, primary, and Carpenter, Erica L., primary

Published
2023
Full Text
View/download PDF

23. Supplemental Table 5 from Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA

Author

Thompson, Jeffrey C., primary, Yee, Stephanie S., primary, Troxel, Andrea B., primary, Savitch, Samantha L., primary, Fan, Ryan, primary, Balli, David, primary, Lieberman, David B., primary, Morrissette, Jennifer D., primary, Evans, Tracey L., primary, Bauml, Joshua, primary, Aggarwal, Charu, primary, Kosteva, John A., primary, Alley, Evan, primary, Ciunci, Christine, primary, Cohen, Roger B., primary, Bagley, Stephen, primary, Stonehouse-Lee, Susan, primary, Sherry, Victoria E., primary, Gilbert, Elizabeth, primary, Langer, Corey, primary, Vachani, Anil, primary, and Carpenter, Erica L., primary

Published
2023
Full Text
View/download PDF

24. Supplemental Table 4 from Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA

Author

Thompson, Jeffrey C., primary, Yee, Stephanie S., primary, Troxel, Andrea B., primary, Savitch, Samantha L., primary, Fan, Ryan, primary, Balli, David, primary, Lieberman, David B., primary, Morrissette, Jennifer D., primary, Evans, Tracey L., primary, Bauml, Joshua, primary, Aggarwal, Charu, primary, Kosteva, John A., primary, Alley, Evan, primary, Ciunci, Christine, primary, Cohen, Roger B., primary, Bagley, Stephen, primary, Stonehouse-Lee, Susan, primary, Sherry, Victoria E., primary, Gilbert, Elizabeth, primary, Langer, Corey, primary, Vachani, Anil, primary, and Carpenter, Erica L., primary

Published
2023
Full Text
View/download PDF

32. Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non–small-cell lung cancer

Author

Forde, Patrick M, primary, Spicer, Jonathan, additional, Lu, Shun, additional, Provencio, Mariano, additional, Mitsudomi, Tetsuya, additional, Awad, Mark M, additional, Felip, Enriqueta, additional, Broderick, Stephen R, additional, Brahmer, Julie R, additional, Swanson, Scott J, additional, Kerr, Keith, additional, Wang, Changli, additional, Ciuleanu, Tudor–Eliade, additional, Saylors, Gene B, additional, Tanaka, Fumihiro, additional, Ito, Hiroyuki, additional, Chen, Ke Neng, additional, Liberman, Moishe, additional, Vokes, Everett E, additional, Taube, Janis M, additional, Dorange, Cecile, additional, Cai, Junliang, additional, Fiore, Joseph, additional, Jarkowski, Anthony, additional, Balli, David, additional, Sausen, Mark, additional, Pandya, Dimple, additional, Calvet, Christophe Y, additional, and Girard, Nicolas, additional

Published
2023
Full Text
View/download PDF

34. Deep computational image analysis of immune cell niches reveals treatment-specific outcome associations in lung cancer

Author

Barrera, Cristian, Corredor, Germán, Viswanathan, Vidya Sankar, Ding, Ruiwen, Toro, Paula, Fu, Pingfu, Buzzy, Christina, Lu, Cheng, Velu, Priya, Zens, Philipp, Berezowska, Sabina, Belete, Merzu, Balli, David, Chang, Han, Baxi, Vipul, Syrigos, Konstantinos, Rimm, David L, Velcheti, Vamsidhar, Schalper, Kurt, Romero, Eduardo, and Madabhushi, Anant

Subjects
570 Life sciences, biology, 610 Medicine & health
Abstract

The tumor immune composition influences prognosis and treatment sensitivity in lung cancer. The presence of effective adaptive immune responses is associated with increased clinical benefit after immune checkpoint blockers. Conversely, immunotherapy resistance can occur as a consequence of local T-cell exhaustion/dysfunction and upregulation of immunosuppressive signals and regulatory cells. Consequently, merely measuring the amount of tumor-infiltrating lymphocytes (TILs) may not accurately reflect the complexity of tumor-immune interactions and T-cell functional states and may not be valuable as a treatment-specific biomarker. In this work, we investigate an immune-related biomarker (PhenoTIL) and its value in associating with treatment-specific outcomes in non-small cell lung cancer (NSCLC). PhenoTIL is a novel computational pathology approach that uses machine learning to capture spatial interplay and infer functional features of immune cell niches associated with tumor rejection and patient outcomes. PhenoTIL's advantage is the computational characterization of the tumor immune microenvironment extracted from H&E-stained preparations. Association with clinical outcome and major non-small cell lung cancer (NSCLC) histology variants was studied in baseline tumor specimens from 1,774 lung cancer patients treated with immunotherapy and/or chemotherapy, including the clinical trial Checkmate 057 (NCT01673867).

Published
2023
Full Text
View/download PDF

35. Density patterns of tumor-infiltrating lymphocytes and association with objective response to nivolumab in patients with lung adenocarcinoma from CheckMate 057.

Author

Corredor, Germán, primary, Ding, Ruiwen, additional, Prasanna, Prateek, additional, Barrera, Cristian, additional, Toro, Paula, additional, Viswanathan, Vidya Sankar, additional, Zens, Philipp, additional, Berezowska, Sabina, additional, Baxi, Vipul, additional, Balli, David, additional, Belete, Merzu, additional, Velcheti, Vamsidhar, additional, Schalper, Kurt A., additional, and Madabhushi, Anant, additional

Published
2022
Full Text
View/download PDF

36. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

Author

Forde, Patrick M., primary, Spicer, Jonathan, additional, Lu, Shun, additional, Provencio, Mariano, additional, Mitsudomi, Tetsuya, additional, Awad, Mark M., additional, Felip, Enriqueta, additional, Broderick, Stephen R., additional, Brahmer, Julie R., additional, Swanson, Scott J., additional, Kerr, Keith, additional, Wang, Changli, additional, Ciuleanu, Tudor-Eliade, additional, Saylors, Gene B., additional, Tanaka, Fumihiro, additional, Ito, Hiroyuki, additional, Chen, Ke-Neng, additional, Liberman, Moishe, additional, Vokes, Everett E., additional, Taube, Janis M., additional, Dorange, Cecile, additional, Cai, Junliang, additional, Fiore, Joseph, additional, Jarkowski, Anthony, additional, Balli, David, additional, Sausen, Mark, additional, Pandya, Dimple, additional, Calvet, Christophe Y., additional, and Girard, Nicolas, additional

Published
2022
Full Text
View/download PDF

37. MYC Levels Regulate Metastatic Heterogeneity in Pancreatic Adenocarcinoma

Author

Maddipati, Ravikanth, primary, Norgard, Robert J., additional, Baslan, Timour, additional, Rathi, Komal S., additional, Zhang, Amy, additional, Saeid, Asal, additional, Higashihara, Taku, additional, Wu, Feng, additional, Kumar, Angad, additional, Annamalai, Valli, additional, Bhattacharya, Saurav, additional, Raman, Pichai, additional, Adkisson, Christian A., additional, Pitarresi, Jason R., additional, Wengyn, Maximilian D., additional, Yamazoe, Taiji, additional, Li, Jinyang, additional, Balli, David, additional, LaRiviere, Michael J., additional, Ngo, Tuong-Vi C., additional, Folkert, Ian W., additional, Millstein, Ian D., additional, Bermeo, Jonathan, additional, Carpenter, Erica L., additional, McAuliffe, John C., additional, Oktay, Maja H., additional, Brekken, Rolf A., additional, Lowe, Scott W., additional, Iacobuzio-Donahue, Christine A., additional, Notta, Faiyaz, additional, and Stanger, Ben Z., additional

Published
2021
Full Text
View/download PDF

40. MYCcontrols metastatic heterogeneity in pancreatic cancer

Author

Maddipati, Ravikanth, primary, Norgard, Robert J., additional, Baslan, Timour, additional, Rathi, Komal S., additional, Zhang, Amy, additional, Raman, Pichai, additional, Pitarresi, Jason R., additional, Wengyn, Maximilian D., additional, Yamazoe, Taiji, additional, Li, Jinyang, additional, Balli, David, additional, LaRiviere, Michael J., additional, Folkert, Ian W., additional, Millstein, Ian D., additional, Bermeo, Jonathan, additional, Carpenter, Erica L., additional, Lowe, Scott, additional, Iacobuzio-Donahue, Christine, additional, Notta, Faiyaz, additional, and Stanger, Ben Z., additional

Published
2021
Full Text
View/download PDF

41. Abstract PO-053: MYC Influences metastatic heterogeneity in pancreatic cancer

Author

Maddipati, Ravikanth, primary, Norgard, Robert J., additional, Baslan, Timour, additional, Rathi, Komal S., additional, Zhang, Amy, additional, Raman, Pichai, additional, Wengyn, Max D., additional, Yamazoe, Taiji, additional, Li, Jinyang, additional, Balli, David, additional, LaRiviere, Michael J., additional, Folkert, Ian W., additional, Millstein, Ian D., additional, Bermeo, Jonathan, additional, Carpenter, Erica L., additional, Lowe, Scott, additional, Iacobuzio-Donahue, Christine, additional, Notta, Faiyaz, additional, and Stanger, Ben Z., additional

Published
2020
Full Text
View/download PDF

43. Listeria monocytogenes personalized cancer vaccines drive therapeutic immune responses to cancer derived neoantigens

Author

Coder, Brandon, primary, Pryshchep, Olga, additional, Kelkar, Dipti, additional, Filippova, Elena, additional, Ju, Xiaoming, additional, Balli, David, additional, Mottershead, Cristina, additional, Ramos, Kim, additional, Thambi, Nithya, additional, Cheng, Zhiyong, additional, Lugt, Bryan Vander, additional, Lesch, Justin, additional, Liu, Xian, additional, DeVoss, Jason, additional, Cooke, Keegan, additional, Liu, Siyuan, additional, Zhan, Jinghui, additional, Mitchell, Petia, additional, Villarreal, Daniel O, additional, Hayes, Sandra M., additional, Johnston, James A, additional, Petit, Robert, additional, Phee, Hyewon, additional, and Princiotta, Michael F., additional

Published
2020
Full Text
View/download PDF

45. Abstract B38: Calcium signaling induces a partial EMT in pancreatic ductal adenocarcinoma

Author

Norgard, Robert J., primary, Maddipati, Ravikanth, additional, Aiello, Nicole M., additional, Balli, David, additional, Pitarresi, Jason R., additional, Rosario-Berrios, Derick N., additional, Li, Jinyang, additional, Yuan, Salina, additional, Yamazoe, Taiji, additional, Sela, Yogev, additional, Merrell, Allyson J., additional, Wengyn, Maximilian D., additional, Sun, Kathryn, additional, Rustgi, Anil K., additional, and Stanger, Ben Z., additional

Published
2019
Full Text
View/download PDF

46. PP01.118 First-line Nivolumab (N) + Ipilimumab (I) + Chemotherapy (C) in Metastatic NSCLC (mNSCLC): CheckMate 9LA 4-Year Clinical Update

Author

Badin, Firas, Carbone, David P., Ciuleanu, Tudor-Eliade, Schenker, Michael, Cobo-Dols, Manuel, Bordenave, Stephanie, Juan-Vidal, Oscar, Menezes, Juliana, Reinmuth, Niels, Richardet, Eduardo, Cheng, Ying, Mizutani, Hideaki, Paz-Ares, Luis G., Lu, Shun, John, Thomas, Zhang, Xiaoqing, Hu, Nan, Balli, David, Baxi, Vipul, Neely, Jaclyn, and Reck, Martin

Published
2024
Full Text
View/download PDF

47. Abstract CT007: Safety and immunogenicity of a personalized neoantigen-Listeria vaccine in cancer patients

Author

Hecht, J. Randolph, primary, Goldman, Jonathan W., additional, Hayes, Sandy, additional, Balli, David, additional, Princiotta, Michael F., additional, Dennie, Justin G., additional, Heyburn, John, additional, Sands, Tammy, additional, Sheeri, Sumitra, additional, Petit, Robert, additional, Gutierrez, Andres A., additional, and Tsai, Frank, additional

Published
2019
Full Text
View/download PDF

48. Abstract CT007: Safety and immunogenicity of a personalized neoantigen-Listeriavaccine in cancer patients

Author

Hecht, J. Randolph, primary, Goldman, Jonathan W., additional, Hayes, Sandy, additional, Balli, David, additional, Princiotta, Michael F., additional, Dennie, Justin G., additional, Heyburn, John, additional, Sands, Tammy, additional, Sheeri, Sumitra, additional, Petit, Robert, additional, Gutierrez, Andres A., additional, and Tsai, Frank, additional

Published
2019
Full Text
View/download PDF

49. Abstract LB-149: Targeting shared hotspot cancer mutations with aListeria monocytogenesimmunotherapy induce potent anti-tumor immunity

Author

Villarreal, Daniel, primary, Coder, Brandon, additional, Armington, Susan, additional, L'Huillier, Andrew, additional, Mottershead, Cristina, additional, Filippova, Elena, additional, Thambi, Nithya, additional, Ramos, Kim, additional, Balli, David, additional, Petit, Robert, additional, and Princiotta, Michael, additional

Published
2018
Full Text
View/download PDF

50. Abstract LB-148: Targeting frameshift mutations with aListeria monocytogenesimmunotherapy drives neoantigen-specific antitumor immunity in the MC38 and CT26 mouse tumor models

Author

Coder, Brandon, primary, Villarreal, Daniel O., additional, Armington, Susan, additional, Filippova, Elena, additional, L'Huillier, Andrew, additional, Kelkar, Dipti, additional, Ju, Xiaoming, additional, Mottershead, Cristina, additional, Balli, David, additional, Ramos, Kim, additional, Phee, Hyewon, additional, Johnston, Jim, additional, Petit, Robert, additional, and Princiotta, Michael, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results